Welcome to our dedicated page for Sensei Biotherapeutics SEC filings (Ticker: SNSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking clinical-stage biotech disclosures is never easy. Sensei Biotherapeutics’ pursuit of tumor-microenvironment activated antibodies produces dense risk factor pages, intricate R&D cost tables, and frequent funding 8-Ks. If you’ve ever opened the 10-K looking for VISTA trial data or sifted through Sensei Biotherapeutics insider trading Form 4 transactions, you know the challenge.
Stock Titan’s AI scans every Sensei Biotherapeutics quarterly earnings report 10-Q filing, delivers Sensei Biotherapeutics Form 4 insider transactions real-time, and offers Sensei Biotherapeutics SEC filings explained simply. Our platform highlights pipeline milestones, cash runway updates, and shelf-registration details in plain language. Whether you want a quick Sensei Biotherapeutics earnings report filing analysis or are understanding Sensei Biotherapeutics SEC documents with AI for deeper diligence, the answers surface in seconds.
Dive deeper without drowning in jargon. Compare option grants via Sensei Biotherapeutics executive stock transactions Form 4, skim a Sensei Biotherapeutics annual report 10-K simplified summary, or review the Sensei Biotherapeutics proxy statement executive compensation section to spot incentive shifts. Real-time alerts flag every Sensei Biotherapeutics 8-K material events explained, from trial pauses to capital raises. Investors use these insights to monitor insider sentiment before catalysts, track quarter-over-quarter R&D spend, and evaluate dilution risk—all without downloading massive PDFs. Our AI-powered summaries, expert context, and complete filing coverage turn regulatory complexity into actionable clarity.
Sensei Biotherapeutics, Inc. (SNSE) reported the initial shareholdings of its President and Principal Executive Officer as of 11/14/2025. The executive directly beneficially owns 1,574 shares of common stock, primarily in the form of restricted stock units, with 1,444 shares already vested and 130 shares scheduled to vest in two equal installments on February 15, 2026 and February 15, 2027, subject to continued service.
The executive also holds multiple stock options to purchase common stock with different exercise prices and vesting schedules. These options cover separate grants that generally vest monthly over thirty-six months from their respective commencement dates, with one grant vesting 100% on December 1, 2025, all conditioned on continued service with Sensei Biotherapeutics.
Sensei Biotherapeutics (SNSE) reported Q3 results and outlined major changes to its business. The company posted a net loss of
Sensei discontinued development of its lead program, solnerstotug, and began a review of strategic alternatives, which could include asset sales, licensing, a merger, or an orderly wind-down. To preserve cash, it plans a workforce reduction of approximately 65%, expecting cash charges of about
The company effected a 1‑for‑20 reverse stock split on June 16, 2025. Shares outstanding were 1,261,290 as of November 10, 2025. With R&D at
Sensei Biotherapeutics (SNSE) filed an 8-K announcing it furnished a press release with financial results for the quarter ended September 30, 2025. The disclosure appears under Item 2.02, with the company stating the information "shall not be deemed filed" for purposes of Section 18 of the Exchange Act.
The press release is included as Exhibit 99.1. Sensei’s common stock trades on Nasdaq under the symbol SNSE.
Sensei Biotherapeutics (SNSE) furnished an update under Item 7.01, announcing it has initiated a strategic review to maximize shareholder value. The company disclosed this via a press release titled “Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value,” furnished as Exhibit 99.1. The disclosure is provided under Regulation FD and is not deemed filed under the Exchange Act.
Sensei Biotherapeutics (SNSE) furnished an update via Form 8-K. The company shared a press release titled “Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025,” and noted a webcast to discuss the clinical trial results. The company also updated its corporate presentation.
Both the press release (Exhibit 99.1) and the corporate presentation (Exhibit 99.2) were provided under Item 7.01 and are being furnished, not filed, and are not incorporated by reference under the Exchange Act or Securities Act.
What happened: Sensei Biotherapeutics issued a press release announcing its financial results for the quarter ended June 30, 2025.
Why it matters: The press release is attached to this Form 8-K as Exhibit 99.1, so investors can read the company’s reported results and commentary. The filing explicitly states the exhibit is being furnished, not filed, and therefore is not treated the same as a formally filed disclosure or incorporated by reference.
What to do: Review Exhibit 99.1 for the actual figures and management comments, since this 8-K itself does not include the financial numbers.
FAQ
What is the current stock price of Sensei Biotherapeutics (SNSE)?
What is the market cap of Sensei Biotherapeutics (SNSE)?
